- Report
- October 2020
- 150 Pages
Global
From €2692EUR$2,800USD£2,310GBP
- Report
- June 2020
- 753 Pages
Global
From €3173EUR$3,300USD£2,722GBP
- Report
- March 2020
- 330 Pages
Global
From €2885EUR$3,000USD£2,475GBP
- Report
- January 2021
- 900 Pages
United States
From €3173EUR$3,300USD£2,722GBP
- Report
- April 2023
- 120 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- August 2020
- 115 Pages
Global
From €4087EUR$4,250USD£3,506GBP
- Report
- January 2022
- 92 Pages
Global
From €6683EUR$6,950USD£5,733GBP
- Report
- March 2018
- 118 Pages
Global
From €4087EUR$4,250USD£3,506GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- January 2019
- 51 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- October 2018
- 17 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- May 2021
- 160 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Report
- July 2020
- 1740 Pages
Global
From €4615EUR$4,800USD£3,959GBP
- Report
- February 2024
- 89 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
- Report
- April 2023
- 160 Pages
Global
From €5768EUR$5,999USD£4,948GBP
- Report
- April 2023
- 147 Pages
Global
From €5768EUR$5,999USD£4,948GBP
Cyclophosphamide is a drug used to treat immune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and vasculitis. It is a type of alkylating agent, which works by inhibiting the growth of certain cells in the body. It is usually administered intravenously or orally, and is often used in combination with other drugs. Cyclophosphamide is also used to treat certain types of cancer, such as lymphoma and leukemia.
Cyclophosphamide is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other drugs. It is generally well tolerated, with few side effects. However, it can cause serious side effects, such as bone marrow suppression, and should be used with caution.
Some of the companies in the Cyclophosphamide market include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. Show Less Read more